{"schema_version":"secwatch.filing_event.v1","accession":"0001645666-25-000036","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.552120+00:00","generated_at":"2026-05-17T13:56:58.410499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kezar Life Sciences Q2 net loss $13.7M; FDA lifts partial hold on AIH trial","bullets":["Net loss $13.7M ($1.87/share) vs $21.5M loss in Q2 2024; R&D expenses down 41% to $9.6M.","Cash, equivalents & marketable securities $100.8M as of June 30, 2025 ($132.2M at Dec 31, 2024).","FDA removed partial clinical hold on PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis.","Submitted Type C meeting request to FDA for Q4 2025 to discuss registration-enabling AIH study design.","PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025 (Nov 7-11)."],"urls":{"canonical":"https://secwatch.observer/filing/0001645666-25-000036","json":"https://secwatch.observer/filing/0001645666-25-000036.json","markdown":"https://secwatch.observer/filing/0001645666-25-000036.md","text":"https://secwatch.observer/filing/0001645666-25-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000164566625000036/0001645666-25-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000164566625000036/kzr-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:56:58.410499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}